Firebrick Pharma secures key Nasodine patent in the Philippines
Firebrick Pharma has announced the acceptance of a key patent titled “Prevention of infection by highly pathogenic viruses using topical application of povidone-iodine on mucous membranes” in the Philippines. The Firebrick Pharma Nasodine Philippines Patent extends protection until 2040 and covers the use of Nasodine Nasal Spray and other intranasal povidone-iodine (PVP-I) preparations for reducing SARS-CoV-2 viral load. The Philippines is identified as one of the company’s most commercially strategic markets, with regulatory approval anticipated during 2026.
The patent protects both therapeutic applications and pre-exposure prophylaxis against SARS-CoV-2. This acceptance strengthens Firebrick’s commercial position ahead of the anticipated regulatory approval in a key target market for the (ASX: FRE) listed company.
What the patent protects
The accepted patent covers intranasal PVP-I preparations designed to reduce SARS-CoV-2 viral load in the nose. Crucially, it also extends to preventative use prior to exposure and encompasses multiple product formats beyond nasal spray.
The patent provides protection for:
- Nasodine Nasal Spray
- Other intranasal PVP-I preparations
- Gargle formulations
- Throat spray applications
- Pre-exposure prophylaxis applications
Dr Peter Molloy, Executive Chairman
“This patent is a commercially useful extension to our common cold patent in one of our most important markets, the Philippines. It covers the use of PVP-I in the nose or throat in relation to SARS-CoV-2 and therefore would protect a gargle or throat spray as well as the nasal spray for that purpose.”
This broad coverage positions Firebrick to launch multiple product formats in the Philippines market once regulatory approval is secured, without the immediate threat of generic competition replicating the company’s formulations.
When big ASX news breaks, our subscribers know first
Why patent protection matters for pharmaceutical investors
For investors new to biotechnology, understanding patent protection is fundamental to assessing commercial potential. Patents create legal barriers that prevent competitors from manufacturing or selling identical products for a defined period. This exclusivity allows pharmaceutical companies to maintain pricing power and recover development costs without immediate generic competition eroding market share.
The 2040 expiry date provides Firebrick with approximately 14 years of commercial exclusivity from today’s date. During this protected period, the company can establish market leadership, build brand recognition, and generate revenue without facing price pressure from generic manufacturers attempting to replicate the same therapeutic approach.
Patent protection translates directly to revenue protection. Without it, competitors could immediately copy successful formulations, forcing price reductions that would undermine profitability before development costs are recovered.
Global patent footprint and regulatory pathway
The Firebrick Pharma Nasodine Philippines Patent forms part of a broader international intellectual property strategy. The same patent has been accepted or granted across multiple jurisdictions, providing commercial protection in Firebrick’s key target markets.
| Market | Patent Status | Regulatory Status |
|---|---|---|
| Philippines | Accepted | Approval anticipated 2026 |
| United States | Granted | Approved |
| Europe | Granted | Various |
| Australia | Granted | Approved |
| Singapore | — | Approved |
The combination of patent acceptance and pending regulatory approval positions Firebrick to commence commercial sales in the Philippines once the anticipated 2026 approval is secured. The Philippines represents a strategically important market where patent protection removes a key commercial hurdle before market entry.
Strategic fit within Nasodine expansion plans
The Philippines patent acceptance aligns with Firebrick’s stated expansion strategy. The company has announced plans for up to four products in the Nasodine range and aims to expand sales to up to 10 markets over three years.
Current market presence includes:
- United States (Nasodine Nasal Spray)
- Singapore (Nasodine Nasal Spray and Throat Spray)
- Fiji & South Pacific (Nasodine Nasal Spray and Throat Spray)
- Philippines (pursuing regulatory approval)
Nasodine Nasal Spray has been introduced into the United States, Singapore, and Fiji & South Pacific markets. Nasodine Throat Spray, the first follow-on product, is now available in Singapore and Fiji. The Philippines is explicitly named as a priority market within this expansion roadmap, making the patent acceptance commercially material to the broader growth strategy.
The patent’s coverage of both nasal spray and throat spray formulations provides flexibility for Firebrick to introduce multiple product formats depending on market preference and regulatory feedback in the Philippines.
The next major ASX story will hit our subscribers first
Next steps and investor watchpoints
The immediate catalyst investors should monitor is regulatory approval in the Philippines, which the company anticipates during 2026. Patent acceptance removes intellectual property uncertainty, but commercial sales cannot commence until regulatory approval is granted.
Following regulatory approval, investors should watch for:
- Commercialisation announcements detailing distribution partnerships or direct sales channels
- Product launch timing and initial market penetration data
- Updates on the broader 10-market expansion strategy
- Potential additional product format introductions leveraging the patent’s broad coverage
The Philippines patent acceptance represents a de-risking event. It removes a key commercial hurdle and confirms the company’s freedom to operate without intellectual property challenges once regulatory approval is secured. For investors assessing Firebrick’s commercialisation pathway, the regulatory approval announcement will mark the next material milestone that translates patent protection into revenue-generating activity.
Want to Track Firebrick’s Regulatory Progress in the Philippines?
The Nasodine patent acceptance removes a critical commercial barrier ahead of the anticipated 2026 regulatory decision. With multiple product formats now protected through 2040, the Philippines market represents a significant expansion opportunity for Firebrick Pharma.
For detailed investor information, including updates on regulatory milestones and commercialisation plans, visit the Firebrick Pharma investor centre. Stay informed as the company progresses towards commercial launch in one of its most strategically important markets.
